The efficacy and function of progesterone soft capsules

It is a progesterone drug that can be used to treat dysfunction caused by progesterone deficiency, menstrual disorders caused by ovulatory dysfunction, dysmenorrhea and premenstrual syndrome, bleeding, premenopausal disorders, menopause, and also helps in pregnancy.

About progesterone soft capsules

Progesterone soft capsules were developed by Besins Healthcare Benelux Company and were first approved for marketing in France in 1980. On February 21, 2023, Zhejiang Pharmaceutical announced that the company has recently received the "Drug Supplementary Application Approval Notice" approved and issued by the State Food and Drug Administration for progesterone soft capsules (specification: 0.1g) in three packaging specifications: 6 capsules/bottle, 12 capsules/bottle, and 30 capsules/bottle, which approved the drug to pass the generic drug quality and efficacy consistency evaluation.

The role of progesterone soft capsules

Studies have shown that progesterone capsules are as effective as progesterone injections. At the same time, the drug can be directly absorbed into the blood after being absorbed through the gastrointestinal tract. It has no first-pass metabolism in the liver and can produce higher progesterone concentrations in the patient's body. It can effectively promote the transformation of the endometrium from the proliferative phase to the secretory phase, providing a good pregnancy environment for embryonic development. At the same time, it does not affect metabolism in the body and has few adverse reactions.

Effects of progesterone soft capsules

1. Progesterone soft capsules for the treatment of anovulatory menstrual disorders

Research purpose: To study the treatment of patients with anovulatory menstrual disorder by giving different doses of progesterone soft capsules [1].

Research method: 60 patients with anovulatory menstrual disorder were selected and divided into a control group and an experimental group using random sampling, with 30 cases in each group. The control group was treated with conventional-dose progesterone soft capsules, and the experimental group was treated with high-dose progesterone soft capsules. The clinical efficacy, improvement time of clinical symptoms, and occurrence of adverse reactions were compared between the two groups.

Research results: The total effective rate of treatment in the experimental group was 96.67%, which was significantly higher than the 80.00% in the control group, and the difference was statistically significant (P<0.05). The vaginal bleeding time, menstrual recovery time, and endometrial recovery time in the experimental group were significantly shorter than those in the control group, and the differences were statistically significant (P<0.05). The incidence rate of adverse reactions in the test group was 10.00%, and the incidence rate of adverse reactions in the control group was 10.00%.

The rate was 6.67%, and the difference was not statistically significant (P>0.05).

Research conclusion: High-dose progesterone soft capsules are more effective than conventional dosage in treating patients with anovulatory menstrual disorder. They can accelerate the improvement of patients' clinical symptoms without increasing the incidence of adverse reactions, and are worthy of clinical promotion and application.

2. Progesterone soft capsules for the treatment of infertility due to endometrial polyps

Research purpose: To analyze the clinical effect of progesterone soft capsules combined with hysteroscopic resection in the treatment of infertility due to endometrial polyps.

Research method: 60 infertile patients with endometrial polyps admitted to the Fifth People's Hospital of Datong City from January 2019 to January 2020 were selected and divided into a control group (odd numbers) and an observation group (even numbers) according to the last digit of their admission bed number, with 30 cases in each. The control group was treated with hysteroscopic electroresection, and the observation group was treated with progesterone soft capsules on the basis of the control group. The monthly results of the two groups of patients before and after treatment were compared.

Menstrual volume, endometrial thickness, hemoglobin (Hb) level and hormone level were measured, and the recurrence rate and pregnancy rate of the two groups within 1 year after surgery were calculated.

Research results: After treatment, the menstrual volume of the control group was significantly higher than that of the observation group, the endometrial thickness was significantly greater than that of the observation group, and the Hb level was significantly lower than that of the observation group. The differences were all statistically significant (P<0.05). After treatment, the levels of human chorionic gonadotropin and estradiol in the control group were significantly lower than those in the observation group, and the difference was statistically significant (P<0.05). Within 1 year after surgery, the recurrence rate of the control group was 33.33%, which was significantly higher than the 6.67% of the observation group; the pregnancy rate of the control group was 60.00%, which was significantly lower than the 80.00% of the observation group, and the difference was statistically significant (P<0.05).

Research conclusion: Progesterone soft capsules combined with hysteroscopic resection for infertility with endometrial polyps can not only reduce the patient's menstrual flow, but also reduce the thickness of the endometrium, which is of great significance for improving the body's hormone levels, reducing the recurrence rate, and promoting the pregnancy rate, and is worthy of vigorous promotion.

Summary

Clinical studies have found that the pharmacological effects of progesterone are specifically manifested in promoting endometrial thickening, uterine congestion, and gland growth in the uterine mucosa in the late menstrual cycle. High-dose progesterone can utilize hypothalamic feedback to effectively inhibit pituitary gonadotropin secretion, and at the same time, inhibit ovulation.

References

[1] Gu Lixia, Janal Dushanhali, Qiao Lifeng. Study on the effect of different doses of progesterone soft capsules in the treatment of anovulatory menstrual disorders [J]. Electronic Journal of Practical Gynecological Endocrinology, 2021, 8(10): 59-61. DOI: 10.16484/j.cnki.issn2095-8803.2021.10.011.

Recommended related articles: